ARTICLE | Product Development
Lilly, AbCellera mAb could enable broad deployment for COVID without taxing infusion centers
Bamlanivimab reduces symptomatic COVID-19 by up to 80% in mobile trial
January 22, 2021 2:27 AM UTC
A mobile Phase III prevention study showing a COVID-19 mAb from AbCellera and Lilly reduced symptomatic cases in nursing home residents and staff highlights a strategy that could enable mass deployment without relying on centralized infusion centers.
It also underscores the idea that antiviral mAbs are most effective early in the disease...
BCIQ Target Profiles